Tags : Nurtec

Insights+: Novel Approvals of February 2020

The US FDA has approved multiple NDAs and BLAs in Feb 2020, leading to treatments for patients and advances in health care. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 13 novel products so far in 2020, including 10 in Feb and 3 in Jan […]Read More

Biohaven’s Nurtec Receives the US FDA’s Approval for Treatment of

Shots: The approval is based on P-III study (Study 303) and Study 201 which involves assessing of Nurtec vs PBO in patients with migraine The study resulted in well-tolerated results. Additionally, Biohaven launched a broad suite Nurtec (rimegepant, 75mg) is a first and only calcitonin gene-related peptide (CGRP) receptor antagonist approved by the US FDA […]Read More